The Defender’s Big Pharma Watch delivers the latest headlines related to pharmaceutical companies and their products, including vaccines, drugs, and medical devices and treatments. The views expressed in the below excerpts from other news sources do not necessarily reflect the views of The Defender. Our goal is to provide readers with breaking news that affects human health and the environment.

Paxlovid helps prevent severe COVID-19, but it also might significantly increase a person’s risk of a rebound case, a new study confirms. About 1 in 5 people taking Paxlovid recovered and tested negative for COVID, but later experienced a positive test result and started shedding live and potentially contagious virus.

That’s called “virologic rebound.” It only happened about 2% of the time in people not taking Paxlovid, according to results published Nov. 13 in the Annals of Internal Medicine.

“We found that the virologic rebound phenomenon was much more common than expected — in over 20% of people taking Paxlovid — and that individuals shed live virus when experiencing a rebound, implying the potential for transmission after initially recovering from the virus,” researcher Dr. Mark Siedner, an infectious disease clinician at Massachusetts General Hospital in Boston, said in a news release from Mass General Brigham.

Posted in

Iron Will

Leave a Comment

You must be logged in to post a comment.